Anacor Pharmaceuticals Inc  

(Public, NASDAQ:ANAC)   Watch this stock  
Find more results for ANAC
-0.38 (-2.26%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.87 - 17.08
52 week 4.83 - 23.07
Open 17.00
Vol / Avg. 245,898.00/550,750.00
Mkt cap 688.25M
P/E 9.80
Div/yield     -
EPS 1.68
Shares 41.84M
Beta 1.38
Inst. own 82%
May 8, 2014
Anacor Pharmaceuticals Inc at Deutsche Bank Healthcare Conference - 10:40AM EDT - Add to calendar
May 5, 2014
Q1 2014 Anacor Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 13, 2014
Q4 2013 Anacor Pharmaceuticals Inc Earnings Conference Call
Mar 13, 2014
Q4 2013 Anacor Pharmaceuticals Inc Earnings Release
Mar 3, 2014
Anacor Pharmaceuticals Inc at Cowen Health Care Conference
Feb 24, 2014
Anacor Pharmaceuticals Inc at Citi Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 1540.93% 492.02%
Operating margin 1581.03% 529.00%
EBITD margin - -287.18%
Return on average assets 483.24% 75.94%
Return on average equity 960.40% 134.29%
Employees 79 -
CDP Score - -


1020 East Meadow Circle
PALO ALTO, CA 94303-4230
United States - Map
+1-650-5437500 (Phone)
+1-650-5437660 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Anacor Pharmaceuticals Inc is a United States-based biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company´┐Żs product candidates include topically administered dermatologic compounds-tavaborole (formerly AN2690), a topical antifungal for the treatment of onychomycosis, and AN2728, a topical anti-inflammatory for the treatment of atopic dermatitis and psoriasis. In addition, it is engaged in the development of other wholly-owned clinical product candidates, AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. The Company's clinical pipeline also includes internally developed topical and systemic boron-based compounds in development.

Officers and directors

Paul L. Berns Chairman of the Board, President, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Geoffrey M. Parker Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Kirk R. Maples Ph.D. Senior Vice President - Program Management
Age: 54
Bio & Compensation  - Reuters
Jacob J. Plattner Ph.D. Senior Vice President - Research
Age: 66
Bio & Compensation  - Reuters
Sanjay Chanda Ph.D. Vice President/Interim Head of Drug Development
Age: 48
Bio & Compensation  - Reuters
Lee T. Zane M.D., M.A.S. Vice President-Clinical Development and Interim Chief Medical Officer
Age: 43
Bio & Compensation  - Reuters
Vincent P. Ippolito Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Anders D. Hove M.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Paul H. Klingenstein Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark Leschly Independent Director
Age: 44
Bio & Compensation  - Reuters